ArticleAesthetic surgery journal. Open forum2026
Early Performance of a Multifilament Resorbable Synthetic Mesh in Aesthetic Breast Surgery: A 206 Patient Experience.
Article in Aesthetic surgery journal. Open forum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Increasing evidence supports the role of soft-tissue reinforcement in enhancing outcomes and longevity in breast surgery. Maintenance of lower pole shape, soft-tissue support and implant position often requires use of mesh in aesthetic procedures. The authors describe their experience utilizing a fully resorbable multifilament scaffold (TIGR® Matrix, Novus Scientific, Uppsala, Sweden) as an alternative to biologic and synthetic meshes. Objectives: To assess early safety and performance outcomes when TIGR Matrix is utilized in primary and revision cosmetic breast surgery. Methods: We began routinely utilizing TIGR matrix in aesthetic breast surgeries in 2023 and retrospectively reviewed all patients who underwent primary or revision elective cases with the mesh. Indication for use and examination of product performance was performed via a retrospective review. Results: TIGR matrix was used in 206 patients (407 breasts), mean age 42.6 years, with mean follow-up of 9.2 months. Mean BMI was 24.2 with 30 patients (14.6%) having a history of massive or major weight loss. One hundred fourteen cases (55.3%) were primary procedures, 92 (44.7%) were revisions. Mesh was placed in the subfascial position in 97 (47.1%) cases and submuscular in 109 (52.9%). Ten patients (4.9%) required postoperative intervention; 5 seromas in 4 patients (1.9%) required mesh removal and implant exchange and 6 patients required revision surgeries due to animation deformity (5) and implant displacement (1). Conclusions: Use of TIGR matrix demonstrated early safety and effectiveness, achieving consistent clinical outcomes in both primary and revision aesthetic breast surgeries. Level of Evidence 3 Therapeutic:
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.